Overall, our operating income performance translated to earnings per share of $2.30 for the fourth quarter, up 35% and $8.28 for the full year, up 53%.
Driven by the strength in operating income, fourth quarter earnings per share grew 35% to $2.30 with the full year up 53% to $8.28.
Overall, our operating income performance translated to earnings per share of $2.30 for the fourth quarter, up 35% and $8.28 for the full year, up 53%.
Driven by the strength in operating income, fourth quarter earnings per share grew 35% to $2.30 with the full year up 53% to $8.28.
We delivered double-digit sales and earnings growth in a challenging year.
We currently anticipate total Company sales between $49 billion and $51 billion which translates to sales growth of between 5% and 7%.
We expect to grow our total Company volumes by 2% to 3% next year, outpacing overall protein consumption growth.
On capital loan, we expect to invest $2 billion in fiscal year '22 with a disproportionate share focused on new capacity and automation objectives.
In pursuit of our priority to build financial strength and flexibility, we have substantially de-levered our business over the past 12 months, reducing leverage to 1.2 times net debt to adjusted EBITDA as we paid down $2 billion of debt while growing our earnings and cash flow.
We expect 2% to 3% volume growth on a year-over-year basis as we work to optimize our existing footprint and run our plants full.
We currently anticipate capex spending of approximately $2 billion during fiscal '22, an increase of roughly $800 million.
Liquidity is expected to significantly exceed our target, while net leverage is expected to remain well below 2 times net debt to adjusted EBITDA.
In International and other, we expect margins of 2% to 3% as capacity expansions and strong global demand support volume growth and improved profitability.
We expect to grow our total Company volumes by 2% to 3% next year, outpacing overall protein consumption growth.
On capital loan, we expect to invest $2 billion in fiscal year '22 with a disproportionate share focused on new capacity and automation objectives.
In pursuit of our priority to build financial strength and flexibility, we have substantially de-levered our business over the past 12 months, reducing leverage to 1.2 times net debt to adjusted EBITDA as we paid down $2 billion of debt while growing our earnings and cash flow.
We expect 2% to 3% volume growth on a year-over-year basis as we work to optimize our existing footprint and run our plants full.
We currently anticipate capex spending of approximately $2 billion during fiscal '22, an increase of roughly $800 million.
Liquidity is expected to significantly exceed our target, while net leverage is expected to remain well below 2 times net debt to adjusted EBITDA.
In International and other, we expect margins of 2% to 3% as capacity expansions and strong global demand support volume growth and improved profitability.
Overall, our operating income performance translated to earnings per share of $2.30 for the fourth quarter, up 35% and $8.28 for the full year, up 53%.
Driven by the strength in operating income, fourth quarter earnings per share grew 35% to $2.30 with the full year up 53% to $8.28.
